Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
OS THERAPIES INC (OSTX) Stock Price & Overview
NYSEARCA:OSTX • US68764Y2072
Current stock price
1.63 USD
-0.07 (-4.12%)
Last:
The current stock price of OSTX is 1.63 USD. Today OSTX is down by -4.12%. In the past month the price increased by 25%. In the past year, price decreased by -16.67%.
OSTX Key Statistics
52-Week Range1.15 - 2.57
Current OSTX stock price positioned within its 52-week range.
1-Month Range1.16 - 1.9
Current OSTX stock price positioned within its 1-month range.
- Market Cap
- 68.525M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.14
- Dividend Yield
- N/A
OSTX Stock Performance
Today
-4.12%
1 Week
+17.24%
1 Month
+25.00%
3 Months
+25.00%
Longer-term
6 Months -8.60%
1 Year -16.67%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
OSTX Stock Chart
OSTX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to OSTX. When comparing the yearly performance of all stocks, OSTX turns out to be only a medium performer in the overall market: it outperformed 47.69% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
OSTX Earnings
Next Earnings DateMay 15, 2026
Last Earnings DateMar 31, 2026
PeriodQ4 / 2025
EPS Reported-$0.50
Revenue Reported
EPS Surprise -260.44%
Revenue Surprise %
OSTX Forecast & Estimates
10 analysts have analysed OSTX and the average price target is 12.24 USD. This implies a price increase of 650.92% is expected in the next year compared to the current price of 1.63.
Analysts
Analysts82
Price Target12.24 (650.92%)
EPS Next Y62.06%
Revenue Next YearN/A
OSTX Index Membership
OSTX is currently included in the following stock indexes tracked on ChartMill.
OSTX Financial Highlights
Over the last trailing twelve months OSTX reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS decreased by -40.85% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-28.75M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -420.41% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%-108.33%
Sales Q2Q%N/A
EPS 1Y (TTM)-40.85%
Revenue 1Y (TTM)N/A
OSTX Ownership
Ownership
Inst Owners4.52%
Shares42.04M
Float32.18M
Ins Owners12.75%
Short Float %4.33%
Short Ratio2.36
OSTX Industry Overview
OSTX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
30%
Outperformed 30% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 23.0
- Average Fwd P/E
- 18.3
- Average Debt/Equity
- 2.2
OSTX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.67 | 373.774B | ||
| AMGN | AMGEN INC | 13.67 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.76 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.99 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.41 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.53 | 25.042B | ||
| INCY | INCYTE CORP | 10.56 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OSTX
Company Profile
OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.
Company Info
IPO: 2024-08-01
OS THERAPIES INC
15825 Shady Grove Road, Suite 135
Rockville MARYLAND US
Employees: 4
Phone: 14102977793
OS THERAPIES INC / OSTX FAQ
Can you describe the business of OS THERAPIES INC?
OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.
Can you provide the latest stock price for OS THERAPIES INC?
The current stock price of OSTX is 1.63 USD. The price decreased by -4.12% in the last trading session.
What is the dividend status of OS THERAPIES INC?
OSTX does not pay a dividend.
What is the ChartMill rating of OS THERAPIES INC stock?
OSTX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the Price/Earnings (PE) ratio of OS THERAPIES INC (OSTX)?
OS THERAPIES INC (OSTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.14).
What is the market capitalization of OSTX stock?
OS THERAPIES INC (OSTX) has a market capitalization of 68.53M USD. This makes OSTX a Micro Cap stock.
What is the outstanding short interest for OS THERAPIES INC?
The outstanding short interest for OS THERAPIES INC (OSTX) is 4.33% of its float.